of the human influenza virus, increase the risk of viral genomic reassortment.Multiple H5N1 vaccine candidates, including mRNA platforms, have been licensed or are advancing, supporting targeted pre-exposure strategies for the high-risk population.Sustained surveillance, rapid characterization and vaccination capacity, ventilation-aware infection control, and transparent risk communication, especially amid the post-COVID skepticism, remain central to mitigating the next influenza pandemic.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: